Aerin Medical Inc.

26 articles about Aerin Medical Inc.

• New Two-Year Results Show Sustained Improvement in Chronic Rhinitis Symptoms Following a Single Procedure with Aerin Medical’s RhinAer®

  2/29/2024

  Aerin Medical Inc. today announced the publication of positive 24-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR).

• Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer®

  2/8/2024

  Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer .

• Aerin Medical Announces Sustained Clinical and Quality-of-Life Improvements Two Years After Chronic Rhinitis Treatment with RhinAer®

  12/5/2023

  Aerin Medical Announces Sustained Clinical and Quality-of-Life Improvements Two Years After Chronic Rhinitis Treatment with RhinAer ®.

• Derrick Sung Joins Aerin Medical as Chief Financial Officer

  11/20/2023

  Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that Derrick Sung has been appointed chief financial officer of the company.

• Aerin Medical Announces Advances for Chronic Rhinitis Treatment with New CPT® Code and Final CMS-Established Payment Rates

  11/3/2023

  Aerin Medical Inc. announced that the Centers for Medicare and Medicaid Services assigned payment for a new Category I Current Procedural Terminology code for endoscopic destruction of the posterior nasal nerve using radiofrequency ablation.

• Aerin Medical Announces New Positive Two-Year Results from VivAer® AERWAY Study

  7/13/2023

  Aerin Medical Inc. today announced the publication of positive two-year follow-up data from the AERWAY trial for patients with severe or extreme nasal airway obstruction (NAO) due to nasal valve collapse (NVC).

• Aerin Medical Supports AAO-HNS Position Recognizing Nasal Valve Repair as a Distinct Procedure that Improves Nasal Obstruction Symptoms

  4/18/2023

  Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, supports the recent American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) position statement.

• Aerin Medical Announces CMS Set to Implement New CPT® Code for Temperature-Controlled Radiofrequency Repair of Nasal Valve Collapse

  11/16/2022

  Aerin Medical Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) assigned physician and facility payment for a new Category I Current Procedural Terminology (CPT®) code that includes the use of VivAer® to repair nasal valve collapse (NVC) when performed in the office and outpatient surgical settings.

• Aerin Medical Announces Establishment of a New CPT® Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation

  10/18/2022

  Aerin Medical Inc. announced that the American Medical Association Current Procedural Terminology Editorial Panel accepted the application for a new Category I CPT code to report endoscopic destruction of the posterior nasal nerve using radiofrequency ablation.

• Aerin Medical Receives FDA Clearance of Next-Generation RhinAer® Stylus for Treatment of Patients with Chronic Rhinitis

  9/8/2022

  Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of a next-generation RhinAer® stylus.

• New 12-month Results from the VATRAC Trial Confirm Durable Efficacy of Aerin Medical’s VivAer® in Patients with Nasal Valve Collapse

  9/6/2022

  Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced that JAMA Otolaryngology – Head & Neck Surgery published positive 12-month active treatment group outcomes from the VATRAC trial.

• New Study of Aerin Medical’s RhinAer® Shows Positive Clinical and Quality-of-Life Results Following Treatment for Chronic Rhinitis

  7/19/2022

  Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & Allergy.

• New 12-month Results from RHINTRAC Randomized Controlled Trial Demonstrate Durable Safety and Efficacy of Aerin Medical’s RhinAer® for Treatment of Chronic Rhinitis

  7/6/2022

  Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive 12-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR).

• Four-Year Results Show Aerin Medical’s VivAer® Treatment Provides Significant, Sustained Relief of Nasal Obstruction Symptoms

  6/29/2022

  Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced that the International Forum of Allergy & Rhinology published positive four-year results from a VivAer® clinical trial.

• Aerin Medical Secures $60 Million in Equity Financing

  6/16/2022

  Aerin Medical Inc. a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced it has recently closed a $60 million equity financing.

• Aerin Medical’s RhinAer® Demonstrates Long-term Safety and Efficacy for Treatment of Chronic Rhinitis in Newly Published Two-year Study

  6/7/2022

  Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication in Allergy and Rhinology of positive two-year results from a trial evaluating the safety and efficacy of RhinAer® in patients with chronic rhinitis.

• Results Published from RHINTRAC Randomized Controlled Trial Demonstrate Safety and Efficacy of Aerin Medical’s RhinAer® For Treatment of Chronic Rhinitis

  9/13/2021

  Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication of positive results from the RHINTRAC clinical trial in OTO Open.

• Positive Aerin Medical AERWAY Study Results Published Showing Effectiveness of VivAer® for Nasal Obstruction Patients With Nasal Valve Collapse

  8/5/2021

  Aerin Medical, Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal airway conditions, today announced the publication of the AERWAY study showing the safety and efficacy of VivAer® for treating patients with nasal airway obstruction (NAO) due to nasal valve collapse (NVC)

• Two-Year Results Demonstrating Long-Term Effectiveness of Aerin Medical’s VivAer® Treatment of Nasal Obstruction Published in International Forum of Allergy & Rhinology

  4/19/2021

  Two-Year Results Demonstrating Long-Term Effectiveness of Aerin Medical’s VivAer ® Treatment of Nasal Obstruction Published in International Forum of Allergy &Rhinology Data shows in-office treatment of nasal valve collapse resulted in lasting improvement in symptoms and quality of life SUNNYVALE, Calif.--( BUSINESS WIRE )-- Aerin Medical today announced the publication of two-year results from a multi-center, prospective study that demonstra

• Aerin Medical Announces Appointment of Matt Brokaw as President and CEO and Closing of $48MM Equity Financing

  8/17/2020

  Aerin Medical, a privately held medical device company focused on non-invasive procedures for treating nasal airway conditions, today announced the closing of a $48 million equity financing